- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04517032
ColoRectal Cancer in India: catastrOphiC expenDIture and Referral Pathways infLuencE on Presentation and Treatment (CROCODILE)
Studieöversikt
Status
Detaljerad beskrivning
Objective: To identify a vulnerable group of colorectal cancer patients in India who cannot afford or are unable to comply with a treatment plan for colorectal cancer.
Aims:
- To identify the proportion of CRC patients suffering catastrophic expenditure due to out-of-pocket payments for cancer treatment.
- To determine the proportion of patients who are unable to comply with the treatment plan for CRC, at 6 weeks, 3 months and 6 months after diagnosis.
- To identify barriers and solutions to CRC treatment compliance. Design: A mixed-methods study comprising quantitative pilot data from 3 tertiary cancer centres and qualitative work from interviews with patients and healthcare professionals.
Participants: Patients diagnosed with primary colorectal cancer.
Outcomes:
Primary outcome:
• Incidence of catastrophic expenditure due to out-of-pocket payments for cancer care at 3 timepoints: 6 weeks, 3 months and 6 months after CRC diagnosis.
Secondary outcomes:
- Compliance to the initial treatment plan at three timepoints: 6 weeks, 3 months and 6 months after CRC diagnosis.
- Patients and healthcare professionals perspectives on patient compliance to CRC treatment.
- Identify the 5 main drivers (items charged to the patient) of CRC treatment cost.
- Colorectal cancer stage at the time of diagnosis.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria
- Adults aged 18+ years old. AND
Consecutive new patients with a histopathology proven colorectal cancer for whom a CRC treatment plan is made:
- In an multi-disciplinary team meeting (MDT);
- OR in the outpatient clinic where an MDT is not available (surgery, oncology or radiotherapy outpatient clinic).
AND
• Undergoing treatment in the hospital where the MDT took place
Exclusion Criteria
- Patients with no histopathology available
- Telephone follow-up not possible
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Catastrophic Expenditure at 6 months
Tidsram: 6 months after treatment decision
|
Catastrophic expenditure (CE) will be defined as out of pocket payments for CRC treatment greater than 40% of patient income (assessed by an in-person questionnaire led by a researcher).
|
6 months after treatment decision
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Catastrophic Expenditure at 6 weeks
Tidsram: 6 weeks after treatment decision
|
Catastrophic expenditure (CE) will be defined as out of pocket payments for CRC treatment greater than 40% of patient income (assessed by an in-person questionnaire led by a researcher).
|
6 weeks after treatment decision
|
Catastrophic Expenditure at 3 months
Tidsram: 3 months after treatment decision
|
Catastrophic expenditure (CE) will be defined as out of pocket payments for CRC treatment greater than 40% of patient income (assessed by an in-person questionnaire led by a researcher).
|
3 months after treatment decision
|
Treatment compliance at 6 weeks
Tidsram: 6 weeks after treatment decision
|
A compliant patient will be defined as undergoing or having completed the planned treatment agreed at the time of diagnosis or MDT discussion.
|
6 weeks after treatment decision
|
Treatment compliance at 3 months
Tidsram: 3 months after treatment decision
|
A compliant patient will be defined as undergoing or having completed the planned treatment agreed at the time of diagnosis or MDT discussion.
|
3 months after treatment decision
|
Treatment compliance at 6 months
Tidsram: 6 months after treatment decision
|
A compliant patient will be defined as undergoing or having completed the planned treatment agreed at the time of diagnosis or MDT discussion.
|
6 months after treatment decision
|
Identification of the main drivers of treatment cost
Tidsram: 6 months after treatment decision
|
5 most expensive items or services during colorectal cancer treatment
|
6 months after treatment decision
|
Colorectal cancer stage at the time of diagnosis
Tidsram: At the time of colorectal cancer diagnosis (coincident with timing of patient enrolment in the study)
|
AJCC (American Joint Committee on Cancer) guidance - 8th edition
|
At the time of colorectal cancer diagnosis (coincident with timing of patient enrolment in the study)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Förväntat)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CROC-20200503
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kolorektal cancer
-
Incyte CorporationMerck Sharp & Dohme LLCAvslutadMelanom | Lymfom | Huvud- och halscancer | Magcancer | Äggstockscancer | Hepatocellulärt karcinom (HCC) | Lungcancer | Blåscancer | Endometriecancer | Fasta tumörer | Njurcellscancer (RCC) | Trippel negativ bröstcancer (TNBC) | UC (Urotelial cancer) | Microsatellite-instability (MSI) High Colorectal Cancer (CRC)Förenta staterna